dmarketnftblockchain| Heyuan Biotech's revenue in 2023 will be 205 million yuan in gene therapy CRO business will grow steadily

On the evening of April twenty _ fourthDmarketnftblockchain, and proto-organisms (688238Dmarketnftblockchain.sh) issue the 2023 annual report. During the reporting period, the company achieved operating income of 205 million yuan, of which the gene therapy CRO business showed outstanding performance. during the period, the company actively expanded the service scene, continuously launched new products and tried to expand new areas, and further increased its market share. During the reporting period, the sales revenue of gene therapy CRO business reached 79.4477 million yuan, an increase of 20.56% over the same period last year.

During the reporting period, the company attached importance to R & D and continued to increase R & D investment, continuously enhanced the strength of the R & D team, broadened and prospectively laid out the R & D application direction, and achieved varying degrees of progress in gene therapy basic research and production process development.

Continuous optimization of multi-product line structure

According to public data, Heyuan Biology is a biotechnology company focusing on the technical services of cell and gene therapy, focusing on providing CRO services such as gene therapy vector development and gene function research for the basic research of cell and gene therapy, as well as providing CDMO services such as IND-CMC pharmaceutical research and clinical sample GMP production for the research and development of cell and gene drugs.

In terms of gene therapy CRO business, Heyuan Biology has actively expanded its service scene, continuously launched new products and tried to expand new areas, and expanded its market coverage, which further consolidated the company's position in the industry. In 2023, the sales revenue of gene therapy CRO business reached 79.4477 million yuan, an increase of 20.56% over the same period last year, and continued steady growth. By the end of 2023, it had served a total of 10,000 R & D laboratory customers, with a cumulative increase of more than 20%.

In 2023, Heyuan Biology continued to give full play to its comprehensive and diversified technical advantages. The revenue of gene therapy CDMO business reached 106.9911 million yuan, and important progress was made in the project of CDMO services. By the end of the reporting period, it had helped customers obtain a total of 32 IND approvals from China and the United States, involving oncolytic virus products, AAV gene therapy products, lentivirus products, cell therapy products, plasmids and mRNA products. The cumulative number of service CDMO items exceeds 330, and the new order in 2023 exceeds 250 million yuan.

In addition, on April 21, 2023, "Heyuanzhi Precision Medical Industry Base" opened in Shanghai Lingang New District. It has four bright spots: ultra-large scale, ultra-complete process system, ultra-new process system and intelligent equipment. The reactor has a maximum scale of 2000L and has more than 30 gene cell therapy production lines, including nearly 20 production lines of cell therapy products with different characteristics. Meet the global customer service needs from DNA to IND to NDA. In September 2023, the first phase of the production base was partially put into production, and the production capacity of CDMO was further increased. With the port-adjacent industrial base gradually put into operation, project orders are expected to resume quickly to better meet the fast-growing demand for gene therapy CDMO to support the company's growing order and revenue scale.

Cell and gene therapy products will be on the market in 2023. During the reporting period, according to relevant statistics, a total of 12 cell and gene therapy products have been approved to market in different countries. In the future, under the premise of continuous support and standardization of industrial policy, and under the guidance of more and more unmet clinical needs, gene and cell therapy products will enter the fast lane of development.

Continue to increase investment in research and development

Innovation is the core competitiveness of biopharmaceutical enterprises. Since its establishment, meta-biology has attached equal importance to independent research and development and external cooperation, continuously improve the accessibility and effectiveness of gene and cell therapy products, and consolidate the company's core competitiveness. The company continues to make a comprehensive layout in the optimization of viral packaging system, the development of new viral vectors, the development of cutting-edge non-viral vectors such as mRNA and exosomes, the development of cell culture technology and technology, and the development of platform testing technology to further enrich the R & D team.

In 2023, Heyuan invested 50.917 million yuan in biological research and development, an increase of 46.20 percent over the same period last year, accounting for 24.86 percent of operating income, an increase of 12.90 percent over the same period last year. At present, some of the research and development achievements have been applied to the advanced therapy development of cell gene therapy enterprises. It is expected that in the coming period of time, the company's R & D expenses will continue to grow, and further focus on the technological frontier to improve R & D efficiency.

According to the analysis of the Frost&Sullivan report, it is estimated that by 2025, the global gene therapy market will reach nearly 30.54 billion US dollars, the domestic gene therapy market will reach 17.89 billion yuan, and the market scale will continue to expand. As a leading cell and gene therapy CRO/CDMO company in China, Heyuan Biology will continue to focus on cell and gene therapy segments and empower industry development, consolidate its core competitive advantages, orderly promote overseas markets and international layout, improve capacity utilization, further increase market share, and consolidate and improve the company's dominant position in the same industry.

(article Source: economic reference Network)